Title:

The histone demethylase KDM6B fine-tunes the host response to *Streptococcus pneumoniae*.

Authors:

Michael G. Connor[1], Tiphaine Marie-Noelle Camarasa[1,6], Emma Patey[1ϕ], Orhan Rasid[1], Laura Barrio[2], Caroline M. Weight[5], Daniel P. Miller [4], Robert S. Heyderman[5], Richard J. Lamont[3], Jost Enninga[2], and Melanie A. Hamon[1*]

Affiliations:

[1] Institut Pasteur, G5 Chromatin and Infection, Paris, France

[2] Institut Pasteur, Dynamics of Host-Pathogen Interactions Unit, Paris, France

[3] University of Louisville, Department of Oral Immunology and Infectious Diseases, School of Dentistry, Louisville, Kentucky, United States of America

[4] Virginia Commonwealth University School of Medicine Department of Microbiology and Immunology, Richmond, Virginia, United States of America

[5] Division of Infection and Immunity, University College London, London, UK.

[6] Université Paris Diderot, Sorbonne Paris Cité, Paris, France

[ϕ] Current address University of Glasgow, Scotland, UK

* Corresponding author: Melanie Hamon (melanie.hamon@pasteur.fr)

Abstract:

Streptococcus pneumoniae is a natural colonizer of the human upper respiratory tract and an opportunistic pathogen. After colonization, bacteria either remain in the human upper respiratory tract, or may progress to cause pneumococcal disease. Although epithelial cells are among the first to encounter pneumococci, the cellular processes and contribution of epithelial cells to the host response are poorly understood. Here, we show a *S. pneumoniae* serotype 6B ST90 strain, which does not cause disease in a murine infection model, induces a unique NF-κB signature response distinct from an invasive disease causing isolate of serotype 4 (TIGR4). This signature is characterized by activation of p65 (RelA) and requires a histone demethylase, KDM6B. At the molecular level, we show that interaction of the 6B strain with epithelial cells leads to chromatin remodeling within the IL-11 promoter in a KDM6B dependent manner, where KDM6B specifically demethylates histone H3 lysine 27 di-methyl. Chromatin remodeling of the IL-11 locus facilitates p65 access to three NF-κB sites, which are otherwise inaccessible when stimulated by IL-1β or TIGR4. Finally, we demonstrate through chemical inhibition of KDM6B, with GSK-J4 inhibitor, and through exogenous addition of IL-11 that the host responses to 6B ST90 and TIGR4 strains can be interchanged both *in vitro* and in a murine model of infection *in vivo*. Our studies hereby reveal how a chromatin modifier governs cellular responses during infection.

39 **Introduction**:

40 *Streptococcus pneumoniae* (the pneumococcus), a heterogeneous species comprised of over 90
41 serotypes, naturally colonizes the upper respiratory tract of humans, and is also an opportunistic
42 pathogen [1-6]. Globally, disease attributed to *S. pneumoniae* infection is a priority due to potential lethality
43 resulting from pneumonia, sepsis, or meningitis [4,7]. Importantly, colonization of the human upper
44 respiratory tract is the natural reservoir for this obligate pathobiont. Here, pneumococcus either remains
45 in the nasopharynx and is eventually cleared, or may progress to cause a disease state [2,3,5,8,9].

46 At these initial stages of pneumococcal-epithelial interaction, the pneumococcus interacts with
47 the host nasopharyngeal epithelial barrier and the innate immune system. Recent insights using the
48 experimental human pneumococcal carriage (EHPC) model have highlighted the essential role of NF-κB
49 driven responses for susceptibility, pathogenesis and transmission of pneumococcus [8,10-13]. However, it is
50 unclear how these cellular processes are shaped at the molecular level, and how they affect the potential
51 progression to pneumococcal disease [14].

52 NF-κB is a master transcriptional regulator of both pro- and anti-inflammatory host responses [15-
53 25]. Briefly, NF-κB is comprised of multiple subunits that form hetero- or homodimers, of which the best
54 characterized subunit is p65 (RelA) [26,27]. Activation of p65 occurs through posttranslational modifications
55 (PTMs), such as phosphorylation of serine 536, in response to cellular sensing of inflammatory stimuli (i.e.
56 lipopolysaccharide (LPS) or interleukin 1 beta (IL-1β)) [27]. Activated p65 binds to a kappa-binding consensus
57 sequence sites within the nucleus to initiate transcription of NF-κB dependent genes [28]. However, cellular
58 signaling alone is not enough, as a full NF-κB response also requires chromatin remodeling at the targeted
59 inflammatory gene loci [15-25].

60 Chromatin is a highly ordered structure of DNA wrapped around histone proteins. Chromatin
61 dynamically shifts between open (euchromatin), and closed (heterochromatin) states, which influence
62 gene accessibility and transcription [29-33]. Switching between these two states is the result of chromatin
63 remodeling enzymes/complexes reading, writing and erasing PTMs on histone tails. The enzymes
64 regulating histone PTMs have been identified, and shown to play important roles in transcriptional
65 responses during cellular signaling events, such as NF-κB responses [15,34]. One of these enzymes is KDM6B
66 (JMJD3), a histone demethylase, associated with NF-κB. KDM6B belongs to the Jumonji C- domain family
67 (JMJD) of histone demethylases, of which KDM6B is the only member expressed universally outside of
68 embryonic development [23,35]. Primarily through peptide studies, KDM6B is thought to target the
69 repressive histone marks, lysine 27 tri-methyl (H3K27me3) and di-methyl (H3K27me2) [23,36-38]. To date,
70 mounting evidence, mainly in macrophages, suggests KDM6B is essential for modulating inflammatory

71 gene expression during wound healing, upon LPS stimulation and for immunological tolerance to anthrax
72 toxin [19-22,39]. However, the role of KDM6B in bacteria induced host responses has not been studied.
73 Herein, we demonstrate a pneumococcal isolate of serotype 6B ST90 CC156 lineage F, which in a
74 murine infection model is contained to the upper respiratory tract and does not cause invasive disease,
75 specifically activates a unique NF-κB signature distinct from the invasive disease causing serotype 4 isolate
76 TIGR4. This signature includes upregulation of KDM6B and the cytokine IL-11 in a human epithelial cell
77 culture model. We show that the promoter of IL-11 is remodeled upon challenge with the 6B strain via
78 KDM6B demethylation of H3K27me2, which allows p65 binding at three NF-κB sites upstream of the IL-11
79 transcription start site. We establish the importance of this process in regulating epithelial cell integrity
80 and show that, *in vivo* and *in vitro,* chemical inhibition of KDM6B causes the 6B strain, which is otherwise
81 non-invasive, to cause disease. Conversely, exogenous addition of recombinant IL-11 during challenge
82 with an invasive TIGR4 isolate leads to better containment of this strain to the upper respiratory tract in
83 a murine model of infection.
84
85 **Results**:
86 Serotype 6B ST90 and TIGR4 display different disease outcomes in a murine model of intranasal infection.
87 Using a murine model of infection, we preformed comparative intranasal challenge studies of
88 pneumococcal isolates TIGR4 (serotype 4) and 6B ST90 CC156 lineage F (serotype 6B; hereafter referred
89 to as 6B). Infection of male mice with 3 - 4x10^6 CFU (Sup. Fig. 1A) of TIGR4 induced rapid weight loss and
90 morbidity, within 4 days post-challenge (Fig. 1A & B). In contrast, the 6B isolate did not cause symptomatic
91 pneumococcal disease, as measured by weight loss and survival, even at an infection dose one log higher
92 than that of TIGR4 (Fig 1A & B). Since the murine host outcomes were drastically different, we chose to
93 study the molecular processes in more detail using the 6B and TIGR4 strains.
94
95 Serotype 6B ST90 actively induces a unique cellular response.
96 To begin dissecting the host processes differentially regulated by the strains 6B and TIGR4, we
97 completed an exploratory microarray of human A549 epithelial cells 2 hrs post-challenge (Sup. Fig 1B). In
98 comparison with uninfected cells, 6B differentially influenced 388 transcripts (200 upregulated and 188
99 downregulated); whilst TIGR4 modulated the expression of 1,205, (143 upregulated and 1,062
100 downregulated) (Sup. Table 1). Strikingly by 2 hrs post challenge a larger proportion of the total genes
101 within the 6B dataset contained NF-κB binding sites in contrast to TIGR4 (12% by 6B vs. 3% by TIGR4; Sup.
102 Fig. 1C). This suggested that early NF-κB regulation of gene transcription influenced the host response to

103 6B. To test this, we selected a panel of 41 genes, which included genes from the microarray (*IL-11, KDM6B*
104 *(JMJD3), PTGS2, CXCL8 (IL-8), FOS* and *JUNB*) and 32 direct targets of NF-κB for testing by RT-PCR. Upon
105 A549 epithelial cell challenge with the 6B strain a significant increase in the expression of *CXCL2, IL-11*,
106 *KDM6B,* and *RELA* in comparison to TIGR4 was observed by 2 hrs (Fig. 1C; Sup. Table 2). This cellular
107 response to the 6B strain was not restricted to A549 type II epithelial cells, but was also observed with
108 nasopharyngeal Detroit 562 and the non-cancer Beas2b epithelial (type II) cell lines as KDM6B and IL-11
109 clustered across cell lines with elevated expression levels for 6B in comparison to TIGR4 (Sup Fig. 1D; Sup.
110 Table 2). We further cross-compared the same panel of genes upon IL-1β stimulation (Sup. Table 2), a
111 known pro-inflammatory stimulus which activates p65 (RelA). Using the relative expression data obtained
112 from RT-PCR of A549 cells, we performed a principal component analysis (PCA) on the expression values
113 for 6B, TIGR4 and IL-1β (Fig. 1D). Comparative analysis of the biplot of the first two components showed
114 three groups (95% confidence ellipses), which accounted for 74.9% of the total variance. Altogether,
115 these data demonstrated 6B was inducing an epithelial cellular response characterized by expression of a
116 subset of inflammatory genes, distinct from both TIGR4 and IL-1β.

117 To determine if RT-PCR expression results for *KDM6B,* one of the genes differentially expressed
118 at 2 hrs post-challenge, were reflected at the protein level, we performed immunofluorescence staining
119 for KDM6B (Fig. 1E; Rep. images Sup. Fig. 1E). A549 cells were challenged with either live or
120 paraformaldehyde-killed 6B and TIGR4 strains. Two hours post-challenge the nuclear signal intensity of
121 KDM6B to DAPI was quantified. For 6B there was a significant increase in KDM6B ($pV \leq 0.0001$) compared
122 to TIGR4 and uninfected cells. We did not see a significant increase in KDM6B signal intensity following
123 challenge with either paraformaldehyde-killed 6B or TIGR4. This showed that increased KDM6B
124 expression is an active process due to pneumococcal-epithelial interaction, as paraformaldehyde fixation
125 not only inactivates pneumococcus, but is known to maintain bacterial morphology including pili, and
126 extracellular polymeric substances, such as capsule [40]. Additionally, we sampled supernatants from
127 Detroit 562 cells 6 hrs post challenge with either 6B or TIGR4, and observed a modest increase in
128 detectable IL-11 (Sup. Fig. 1F).

129 Since KDM6B is part of a larger Jumonji C- domain (JMJD) histone demethylase family, we
130 determined if 6B challenge upregulated additional JMJD demethylases, or was specific to KDM6B. We
131 tested three additional JMJD demethylases (KDM7A, KDM8, and KDM6A (UTX)), and an unrelated
132 methyltransferase (EHMT2) by RT-PCR. KDM6B was the only one to be significantly upregulated by 6B
133 (Sup. Fig. 1G). Together these results show 6B induces a differential transcriptional response in epithelial
134 cells characterized, in part, by upregulation of KDM6B and the cytokine IL-11.

135

136 6B cellular response requires p65 activation and catalytically active KDM6B.

137 A hallmark of NF-κB dependent gene induction is the activation of p65 via phosphorylation at
138 serine 536 (S536) [26]. Thus, we tested if phosphorylation of p65 occurred during 6B challenge. Whole cell
139 lysates were collected 2 hrs post-challenge from HeLa GFP-p65 stable cell line, and were immunoblotted
140 for p65 phosphorylation at S536 (Fig. 2A). In comparison to uninfected cells, both IL-1β (positive control)
141 and 6B induced p65 phosphorylation of S536 (pV≤0.001) whereas TIGR4 did not (Fig. 2B). To determine
142 whether p65 activation by 6B was required for *IL-11* and *KDM6B* expression, we used a chemical inhibitor
143 of p65 activation, BAY 11-7082 [41-43]. A549 cells were pretreated for 3 hrs with 10 µM BAY 11-7082 prior
144 to challenge with 6B, TIGR4 or IL-1β, and gene expression was determined by RT-PCR. BAY 11-7082
145 treatment did not affect viability or gene expression alone in comparison to untreated cells (Sup. Fig. 2A
146 & B; gray bars). As a control for inhibitor effect, we used the gene *PTGS2*, which is known to require p65
147 activation for expression. During 6B challenge no significant effect between untreated (no inhibitor) and
148 DMSO (vehicle control) was observed upon the expression of *PTGS2, IL-11* and *KDM6B*, and under the
149 same conditions *IL-11* and *KDM6B* expression remained 2-fold higher on average in comparison to TIGR4
150 and IL-1β (Fig. 2C; white & light gray bars). Inhibiting p65 activation during 6B, TIGR4 or IL-1β challenge
151 resulted in reduction in *PTGS2* (Fig. 2C; gray bars). The expression of *KDM6B* and *IL-11* were significantly
152 repressed during 6B challenge in the presence of inhibitor (pV≤0.001 and 0.05 respectfully) in comparison
153 to DMSO treated cells (Fig. 2C; gray bars). These data show expression of *IL-11* and *KDM6B* is dependent
154 on p65 activation during 6B challenge of epithelial cells. Previous studies demonstrated KDM6B interacts
155 with p65 for gene activation during keratinocyte wound healing, and ChIP-seq studies found LPS
156 stimulation of macrophages lead to KDM6B regulation of specific inflammatory genes [20,22]. To determine
157 whether KDM6B had an active role in 6B induced expression of *IL-11* and *KDM6B*, we used GSK-J4, an
158 inhibitor of the catalytic JMJ domain of KDM6B [44]. As a control, we chose expression of *PTGS2*, as it is
159 associated with KDM6B and not H3K27me3, thus inhibition of the catalytic activity of KDM6B should have
160 no effect upon its expression [20]. GSK-J4 (10 µM; 24 hrs prior) was used to pretreat A549 cells before
161 challenge with 6B, TIGR4 or IL-1β. GSK-J4 alone had no significant effect on cell viability, or gene
162 expression in comparison to untreated cells, nor did it affect the transcripts of *PTGS2*, *IL-11* or *KDM6B* in
163 TIGR4 and IL-1β challenged cells (Fig. 2C and Sup. Fig. 2A & B; black bars). Whereas, when the catalytic
164 activity of KDM6B was inhibited, more than a 3-fold loss of expression for both *IL-11* and *KDM6B* was
165 observed during 6B challenge compared to DMSO control (Fig. 2C; black bars). GSK-J4 treatment had no

166 effect upon *PTGS2* expression during 6B challenge, demonstrating KDM6B catalytic activity was
167 specifically required for IL-11 expression (Fig. 2C; black bars).
168
169 Chromatin is remodeled within the IL-11 promoter upon 6B challenge.
170 Since, KDM6B is p65 dependent, we addressed whether 6B induced p65 recruitment to KDM6B,
171 and if the expression of *IL-11* required KDM6B dependent chromatin remodeling within the IL-11
172 promoter. We mapped and designed ChIP-qPCR primers to predicted kappa-binding sites within the
173 KDM6B and IL-11 promoter using AliBaba2 software, which curates eukaryotic transcription factor DNA
174 binding motifs from the TRANSFAC® database [45]. Two kappa-binding sites upstream (-880bp, and -41bp)
175 of the *KDM6B* transcriptional start site (TSS) were found, while three kappa-binding sites upstream (-
176 2,077bp, -774bp, and -406bp) of the *IL-11* TSS, and one site downstream (+83bp) were predicted (Fig. 3A
177 & Sup. Fig. 3C). Herein, we obtained chromatin from A549 cells 2 hrs post-challenge with either 6B, TIGR4,
178 or IL-1β with and without chemical inhibition of the catalytic activity of KDM6B. First, we confirmed p65
179 recruitment to kappa-bindings sites within the *KDM6B* promoter using ChIP-qPCR (Sup. Fig. 3A & B). We
180 next used ChIP-qPCR to compare the recovery of p65, and KDM6B at these kappa-binding sites within the
181 *IL-11* promoter. During 6B challenge there was a significant (pV≤0.001) recovery of p65 at kappa-binding
182 sites P6 (25%), P3 (20%) and P2 (10%) in contrast to uninfected conditions (Fig. 3B; 6B dark blue;
183 uninfected white). Furthermore, there was 15% recovery of KDM6B across the same kappa-binding sites
184 in cells challenged with 6B (Fig. 3C; 6B dark blue; uninfected white). In contrast, there was no recruitment
185 of p65 or KDM6B to the kappa-binding sites in IL-1β or TIGR4 challenged cells (Sup. Fig. 3D & E).
186 Recruitment of p65 and KDM6B to these kappa-binding sites was abolished in the presence of the GSK-J4
187 inhibitor (Fig. 3B & C; 6B light blue; uninfected gray). This showed during 6B challenge the promoter of *IL-*
188 *11* was rearranged in a manner requiring the catalytic activity of KDM6B.
189 It has been suggested, mainly through peptide studies, that the enzymatic target of KDM6B is
190 primarily H3K27me3 [38,46]. Thus, we hypothesized chromatin rearrangement within the *IL-11* promoter was
191 a result of KDM6B demethylation of H3K27me3. We used ChIP-qPCR to determine the levels of H3K27me3
192 and H3, for nucleosome occupancy, across the three kappa-binding sites within the *IL-11* promoter.
193 Surprisingly, H3K27me3 was not decreased, in fact there was a slight, but significant (pV≤0.05), increase
194 at the P6 kappa-binding site in comparison to unchallenged cells (Fig. 3D; 6B dark blue; uninfected white).
195 There was no enrichment at any kappa-site during IL-1β or TIGR4 challenge (Sup. Fig. 3F). Furthermore,
196 there were no differences in H3 nucleosome distribution at any of the kappa-binding sites between 6B
197 and uninfected cells (Fig. 3E; 6B dark blue; uninfected white), this was also the case for cells challenged

198 with IL-1β or TIGR4 (Sup. Fig. 3G). In the presence of GSK-J4 the increase of H3K27me3 at the P6 and P2
199 kappa-binding sites was lost in conjunction with a slight but significant increase in H3 nucleosome
200 recovery at P6 (Fig. 3E & D; 6B light blue; uninfected gray). This data showed that during 6B challenge,
201 KDM6B was not demethlyating H3K27me3, and this posttranslational modification seemed to increase
202 across the promoter.

203 Since our data showed an active role for KDM6B enzymatic activity independent of H3K27me3,
204 we tested another proposed substrate of KDM6B, H3K27me2 [37]. Our ChIP-qPCR results showed challenge
205 with 6B induced loss of H3K27me2 at the P6 (pV≤0.01) and variable levels at the P3 and P2 sites within
206 the *IL-11* promoter in comparison to uninfected cells (Fig. 3F; 6B dark blue; uninfected white). Strikingly,
207 when KDM6B enzymatic activity was blocked during 6B challenge demethylation of H3K27me2 was
208 significantly inhibited across all kappa-binding sites (Fig. 3F; 6B light blue; uninfected gray).

209 Together these data show: 1) upon 6B challenge of epithelial cells the promoter of *IL-11* is
210 remodeled through the cooperative role of KDM6B and p65, and 2) KDM6B enzymatic activity is directed
211 toward H3K27me2 and independent of H3K27me3 at these kappa-binding sites.

212

213 <u>KDM6B and IL-11 shapes the cellular response.</u>

214 Since KDM6B plays a role in chromatin remodeling and is necessary for *IL-11* expression, we
215 hypothesized it was controlling expression of the host response to 6B challenge. To address this, we used
216 RT-PCR to test the expression of our panel of 41 genes in the presence of GSK-J4. GSK-J4 significantly
217 dampened expression of *IL-8* (pV≤0.025), *IL-6* (pV≤0.026), *CFS2* (pV≤0.044), *CCL2* (pV≤0.011), *CXCL1*
218 (pV≤0.049), *KDM6B* (pV≤0.033), and *IL-11* (pV≤0.006; Fig. 4A; Sup. Table 3). In parallel, we hypothesized
219 that exogenously adding IL-11, which is regulated by KDM6B, would alter the host response to TIGR4
220 during infection. Therefore, we tested, by RT-PCR, the expression levels of NF-κB regulated genes during
221 TIGR4 challenge supplemented with exogenous IL-11. Exogenous IL-11 modified the host response to
222 TIGR4, as the expression of 13 transcripts were significantly changed (Fig. 4B; Sup. Table 3). These data
223 suggested that KDM6B and IL-11 are differentially modulating the cellular host response to either 6B or
224 TIGR4 at specific gene loci.

225 In order to understand how KDM6B and IL-11 influenced generalized epithelial NF-κB responses,
226 independently of pneumococcal-epithelial signaling events, we used IL-1β to stimulate A549 cells in the
227 presence of either GSK-J4 or IL-11 (Sup. Fig. 4A). Inhibiting the catalytic activity of KDM6B lead to
228 differential expression of multiple genes in comparison to untreated controls. In particular, there was a
229 significant (pV≤0.015) 3-fold repression of the RelB transcript, a negative mediator of RelA induced pro-

230 inflammatory responses [47], and a 0.6-fold increase in the IL-1β transcript, a potent pro-inflammatory
231 cytokine. This comparison suggested inhibiting enzymatic activity of KDM6B lead to dysregulation of
232 RelA/RelB cross talk and resolution. In contrast, exogenous IL-11 differentially regulated specific
233 inflammatory mediators. We observed a significant reduction in *TNF* (pV≤0.030, 5-fold), another acutely
234 pro-inflammatory cytokine. Thus, KDM6B and IL-11 are important regulators of cellular transcription in
235 response to an inflammatory mediator IL-1β, as well as upon infection with pneumococci.

236 Finally, we used principal component analysis to compare how GSK-J4 or IL-11 treatment
237 influenced the gene signatures induced by TIGR4 and 6B during infection. For GSK-J4, the ΔCt values from
238 the gene panels of 6B + GSK-J4, TIGR4, and uninfected (untreated) were used for analysis. The first two
239 components accounted for 53.8% of the variance observed between the treatment groups with three
240 clusters forming across the first two components (60% confidence ellipses). Chemical inhibition of the
241 catalytic activity of KDM6B resulted in the overlap of 6B + GSK-J4 treatment group with TIGR4 in the
242 second dimension (Fig. 4C & Sup. Fig. 4B vector loadings; Sup. Table 3). Using the same approach, we
243 compared the ΔCt values of TIGR4 + IL11, 6B, and uninfected (untreated). Here, the first two components
244 explained 50.5% of the variation with three clusters of the experimental groups (60% confidence ellipses).
245 Exogenous addition of IL-11 during TIGR4 challenge grouped and partially overlapped with the uninfected
246 (untreated) and 6B groups (Fig. 4D & Sup. Fig. 4C vector loadings; Sup. Table 3). Altogether, these data
247 suggest KDM6B and IL-11 play critical roles in moderating host transcription, particularly for a subset of
248 NF-κB responses, and could potentially be used to exogenously interchange the host response to 6B and
249 TIGR4 strains during pneumococcal infection.

250

251 <u>KDM6B and IL-11 contribute to epithelial cell integrity.</u>

252 Our RT-PCR expression data showed inhibition of KDM6B with GSK-J4 and exogenous IL-11 to
253 moderate the host response. Interestingly, previous works demonstrate KDM6B and p65 are both
254 required for keratinocyte wound healing [22]. Using these findings, we hypothesized that KDM6B was
255 involved with maintaining epithelial cell integrity during pneumococcal infection. To test the plasma
256 membrane integrity of epithelial cells challenged with 6B or TIGR4 we used a Trypan blue exclusion assay,
257 as damaged membranes are permissible to dye accumulation, in the presence of GSK-J4 or DMSO 24 hrs
258 prior to challenge (Fig. 5A & B). We observed no difference in either epithelial integrity or cell viability
259 between uninfected cells with GSK-J4 inhibitor by lactate dehydrogenase release (LDH; Fig. 5B & Sup. Fig.
260 5A). Furthermore, epithelial integrity was not compromised during 6B challenge in comparison to
261 uninfected cells (Fig. 5A & B). In contrast, challenge with TIGR4 resulted in 60% epithelial membrane

262 damage (Fig. 5B). Strikingly, inhibition of KDM6B catalytic activity affected epithelial integrity of 6B
263 challenged cells, as shown by a significant 20% (pV≤0.001) increase in plasma membrane permissibility to
264 Trypan entry (Fig. 5B). Since Pneumolysin, a pore forming cholesterol dependent cytolysin (CDC), is a well-
265 documented and conserved virulence factor across all pneumococcal isolates and known to stimulate host
266 responses, we tested if epithelial integrity loss was attributed to differential pneumolysin activity or
267 expression between 6B and TIGR4 [3,48]. We observed no difference in the hemolytic activity in the presence
268 of GSK-J4 inhibitor, nor expression of pneumolysin between 6B and TIGR4 (Sup. Fig. 5B & C). Importantly,
269 LDH assay showed not all Trypan blue positive cells were dead (Sup. Fig. 5A), which is in line with previous
270 toxin studies [49,50]. Overall, these results suggest KDM6B plays a role in mediating cell integrity during 6B
271 challenge.

272 It is known respiratory tract epithelial cells can produce IL-11[51-53], and IL-11 regulates epithelial
273 cell plasma membrane proteins [54] while also modulating inflammatory, healing and mucosa responses [55-
274 58]. We therefore tested if exogenous addition of the cytokine IL-11 could mitigate the loss of epithelial cell
275 integrity during TIGR4 challenge. At the time of challenge, the inoculums of TIGR4 and 6B were
276 supplemented with recombinant human IL-11 cytokine prior to addition to A549 cells. After 2 hrs Trypan
277 blue exclusion assay was performed (Fig. 5C & D). IL-11 at the time of TIGR4 challenge increased cell
278 integrity by 20% (pV≤0.001), in comparison to untreated controls (Fig. 5D). There was no significant effect
279 of exogenous IL-11 on uninfected or 6B challenged cells (Fig. 5D). Furthermore, LDH release showed
280 exogenous IL-11 lowered TIGR4 cytotoxicity by 15% (pV≤0.01; Sup. Fig. 5A). Together this data shows IL-
281 11 contributes to maintaining epithelial cell integrity during pneumococcal challenge.

282 Our data suggested the isolate of serotype 6B induced KDM6B and IL-11 to maintain epithelial
283 integrity. We hypothesized other pneumococcal isolates commonly carried could also induce *IL-11*
284 expression, while isolates associated with symptomatic disease and uncommonly carried would not. To
285 test this, we compared isolates of serotypes 19A (Centre National de Référence des Pneumocoques) and
286 19F [59] (BHN100), which are associated with carriage, and two serotype 1 isolates harboring either a
287 hemolytic or non-hemolytic pneumolysin allele, which are less commonly carried but cause disease states.
288 Isolates of serotype 19A and 19F upregulated *IL-11* expression in A549 epithelial cells in comparison to
289 uninfected cells, whereas the serotype 1 isolates did not (Fig. 5E). To determine if *IL-11* upregulation was
290 specific to pneumococcal isolates, or potentially upregulated by other commensals, we tested five
291 additional oral microbiome constituents. Indeed, *Streptococcus gordonii*, *Streptococcus sanguinis*,
292 *Streptococcus oralis*, *Eikenella corrodens* and *Fusobacterium nucleatum* also upregulated the expression
293 of *IL-11* in immortalized gingival keratinocytes (Sup. Fig. 5D). Together, our data show commonly carried

294 pneumococcal isolates and individual commensal organisms induce *IL-11* expression, suggesting these
295 bacteria induce a common response.
296
297 KDM6B and IL-11 are essential for localized containment of pneumococcus *in vivo*
298 We established *in vitro,* inhibiting KDM6B and exogenous addition of IL-11 were sufficient to
299 interchange cellular integrity to 6B and TIGR4. With this, we hypothesized local inhibition of KDM6B during
300 6B infection of the murine nasal epithelium would promote 6B to escape from the nasopharynx. We
301 challenged mice with 3 - $4x10^6$ CFU of either 6B or TIGR4 mixed with either DMSO (vehicle control) or 5
302 mM GSK-J4. The plated inoculums showed no significant effect of DMSO or GSK-J4 on bacterial viability
303 (Sup. Fig. 6B). Bacterial burden in the nasal lavage (NL), bronchoalveolar lavage fluid (BALF), lungs, and
304 spleens of mice 24 hrs (Sup. Fig. 6A) and 48 hrs (Fig. 6A) post-inoculation were quantified by conventional
305 colony forming unit (CFU) enumeration. Bacterial burdens from 6B and TIGR4 challenged DMSO animals
306 showed on average one log more bacteria across all organs in comparison to TIGR4 by 24 hrs (Sup. Fig.
307 6A; 6B light blue; TIGR4 gray). By 48 hrs, infection with TIGR4 showed a progression of bacteria towards
308 internal organs. The loosely attached bacteria in the NL and BALF decreased, while the burden in the lung
309 and spleen increased in comparison to 24 hrs. However, 6B CFU numbers remained either constant or
310 decreased in all samples (Fig. 6B; 6B light blue). With this data, we concluded 6B was primarily contained
311 within the murine nasal cavity, whereas by 48 hrs post-inoculation TIGR4 had escaped the upper
312 respiratory tract and begun to disseminate from the lungs.
313 However, the addition of GSK-J4 changed the bacterial distribution of 6B. Indeed, GSK-J4 treated
314 animals challenged with 6B showed increased burden across all samples in comparison to the 6B DMSO
315 control group at 24 hrs (Sup. Fig. 6A). Additionally, the recovered bacteria from the NL and BALF in the
316 GSK-J4 6B challenged group was not significantly different from the TIGR4 DMSO group (Sup. Fig. 6A).
317 However, after 24 hrs there was no significant difference in the recovery of TIGR4 from the NL, BALF, lungs
318 or spleens between DMSO or GSK-J4 treated animals (Sup. Fig. 6A; TIGR4 DMSO white, TIGR4 GSK-J4 gray).
319 By 48 hrs post-challenge 6B GSK-J4 animals maintained a significantly (pV≤0.05) high bacterial burden in
320 the BALF and spleen compared to 6B DMSO treated animals (Fig. 6A; 6B DMSO light blue, 6B GSK-J4 dark
321 blue). Importantly in animals treated with GSK-J4 6B, was recovered from the spleen, an organ in which
322 bacteria were mostly undetected in DMSO control animals. GSK-J4 treated animals in the TIGR4 group
323 also showed an increase in bacterial burden at 48 hrs post-challenge in the NL, BALF, lung and spleen,
324 which suggests a basal role of KDM6B in regulating NF-κB responses. Altogether, these data show KDM6B

325 activity is specifically required for localized containment of 6B during infection of the murine nasal cavity,
326 and is potentially a negative regulator of TIGR4 dissemination.

327 In our previous *in vitro* studies exogenous IL-11, at the time of infection, was sufficient to modify
328 the host response to TIGR4. This suggested that localized IL-11 during TIGR4 challenge *in vivo* could
329 potentially delay translocation of the bacteria into the lower respiratory tract and deeper tissues by
330 promoting localized containment in the upper respiratory tract. To address this, animals were intranasally
331 challenged with 3 - 4x10^6 CFU of TIGR4 with or without recombinant mouse IL-11 (final 0.15 ug per mouse;
332 Sup. Fig. 6C) at the time of infection. Supplementation of midlog phase TIGR4 inoculums had no effect on
333 growth (Sup. Fig. 6D). Animal weight, as a read out of symptomatic disease, was monitored over 48 hrs,
334 and the bacterial burden enumerated 48 hrs post-infection from the NL, BALF, lung and spleen (Fig. 6B).
335 By 48 hrs post-infection there was substantial recovery of TIGR4 bacterial burden in the BALF, lung and
336 spleen (Fig. 6B), which accompanied a 10% loss of initial starting weight (Fig. 6C). Together this was
337 indicative of symptomatic pneumococcal disease induced by TIGR4 infection. In contrast, TIGR4 with
338 recombinant mouse IL-11, at the time of intranasal challenge, resulted in 5-fold retention of bacteria
339 within the NL (Fig. 6B; pV≤0.01) in comparison to TIGR4 infection alone. Dissemination of bacteria to
340 internal organs was also diminished, with greater than a one-log difference on average in bacterial burden
341 across the BALF, lung and spleen (Fig. 6B). These bacterial burdens further coincided with a significant 5-
342 10% preservation of initial starting weight at 24 hrs and 48 hrs post-infection in contrast to the TIGR4
343 group (Fig. 6C; pV≤0.05 and pV≤0.001 respectively). Overall, these data demonstrate during TIGR4
344 pneumococcal infection a localized IL-11 response is sufficient to ameliorate symptomatic disease and
345 reduce bacterial dissemination to the lower respiratory tract.

346

347 **Discussion**:

348 Bacterial contact with the epithelial barrier is an essential process that leads to pneumococcal
349 carriage and precedes symptomatic pneumococcal disease [3,5]. However, the molecular and transcriptional
350 processes across the spectrum of host interaction from nasal microbiome constituent to potentially lethal
351 disease states are not completely understood. Towards this end, we first demonstrated the pneumococcal
352 strain 6B ST90 (CC156 lineage F) did not cause symptomatic disease or lethality in contrast to a serotype
353 4 (TIGR4) strain in a murine model of infection. Using these two strains, which induce opposing host
354 outcomes, we completed a human microarray of A549 epithelial cells challenged with either 6B ST90 or
355 TIGR4 pneumococcal strains to better understand the cellular processes involved. We show a serotype 6B
356 isolate differentially regulated 388 genes, with enrichment for NF-κB associated genes in comparison to a

357 TIGR4 strain. Direct comparison of NF-κB regulated genes between 6B and TIGR4 showed that 6B induced
358 a unique transcriptional response that included *KDM6B* and *IL-11* expression, which required
359 phosphorylation of p65. We demonstrate molecularly that the 6B isolate, through the activity of KDM6B,
360 induces remodeling of the IL-11 promoter to reveal three NF-κB sites, which are not accessible during IL-
361 1β or TIGR4 stimulation. Together, this is the first demonstration that a 6B strain remodels chromatin
362 within epithelial cells to support containment in the upper respiratory tract.

363 The lysine demethylase KDM6B has mainly been characterized in cellular development, however
364 a few studies suggest that this particular histone demethylase also fine-tunes inflammatory responses and
365 wound healing downstream of p65 through largely unknown mechanisms [20-23,60-62]. We are the first to
366 report both a biological and molecular role for KDM6B and H3K27me3/2 in regulation of a specific gene
367 locus, IL-11, during bacterial challenge. Surprisingly, although KDM6B was shown to primarily target
368 H3K27me3 and to a lesser extent H3K27me2 [37,38,46], our results suggest KDM6B is selectively
369 demethlyating H3K27me2 and not H3K27me3 at the IL-11 promoter. These results are consistent with
370 previous observations of *Da Santa et al.,* who reported gene regulation by KDM6B independently of
371 H3K27me3 [20]. With this observation, we hypothesize that KDM6B is differentially regulating inflammatory
372 gene expression by selective demethylation of H3K27me2 through either an unknown regulatory element
373 or posttranslational modifications to KDM6B. Future ChIP-seq and proteomic studies with biological
374 stimuli, such as pneumococcus, will yield substantial insight into possible KDM6B complexes, and the
375 dynamics of H3K27me3/2 in epigenetic control of inflammatory signaling cascades.

376 Our findings support the idea that pneumococcal-epithelial interactions may actively induce host
377 responses that promote confinement of bacteria to the upper respiratory tract, leading eventually to
378 clearance. The host inflammatory response is a known contributor to both the commensal and pathogenic
379 lifestyles of pneumococcus, by playing an important role in clearance, transmission and establishment of
380 a replicative niche [3,13,63]. Our results suggest KDM6B, and its regulation of *IL-11* transcription, are key
381 components modulating a localized epithelial host response. In a murine model, chemical inhibition of
382 KDM6B led to the dissemination of an otherwise contained 6B strain to the spleen. Given the role of
383 KDM6B, we show that containment is a host driven mechanism involving the expression of IL-11. Since
384 KDM6B differentially regulates multiple genes, we cannot rule out the possibility there are others with
385 concurrent or synergistic functions with IL-11. However, our IL-11 rescue experiments with TIGR4 suggest
386 a role for IL-11 in locally maintaining a host-limiting/tolerogenic epithelial-pneumococcal host response.
387 Interestingly, IL-11 is known to influence mucus production, cell membrane components, wound healing
388 of gastric ulcers and resistance of endothelial cells to immune mediated injury [54,56,57,64,65]. Promoting this

389 localized response to our serotype 6B ST90 isolate within the nasopharynx, is also reflected in our
390 microarray data, as 52 genes associated with wound healing gene ontology were upregulated by 6B in
391 comparison to TIGR4 (Sup. Table 1). Additionally, 39 of the 52 upregulated wound healing genes were also
392 associated with KDM6B as determined by ChIP-seq studies of macrophages (Sup. Table 1). Within this
393 principle, we propose that some pneumococcal strains, including the 6B strain tested, along with some
394 bacteria of the oral microflora, actively influence their localization within the host through a subset of NF-
395 κB driven "wound healing" genes as a potential means to counter balance a deleterious pro-inflammatory
396 host response within the host. How the localized inflammatory processes and host-mediated confinement
397 influences carriage duration and clearance, transmission, or the impact of micro invasion [13] upon these
398 processes remains to be defined.

399 Through our study of p65 activation by pneumococcus, we find that the 6B isolate activated p65
400 to similar levels as IL-1β, however, the ensuing transcriptomic responses are different. Combining these
401 observations with active remodeling of the IL-11 promoter suggests that under 6B stimulation there are
402 additional p65 interacting partners or posttranslational modifications (PTMs), in conjunction with
403 phosphorylation of serine 536. Such data would support a biological role for "NF-κB barcode hypothesis",
404 where a signature barcode of PTMs on NF-κB mediates a specific gene expression pattern [66,67]. While we
405 have established a link between p65, KDM6B and *IL-11* expression, identification of the p65 PTMs and
406 interacting partners necessary for the NF-κB dependent processes of 6B will advance our understanding
407 of not only pneumococcal induced host responses, but also p65 regulation during tolerogenic
408 inflammatory responses.

409 A meta-analysis conducted by *Brouwer et al*., highlighted single nucleotide polymorphisms (SNPs)
410 associated with *NFKBIA, NFKBIE,* and *TIRAP* correlated with protection, whereas SNPs within NEMO
411 (*IKBKG)* or IRAK4 associated predominantly with increased susceptibility to disease [68]. Analysis of KDM6B
412 and H3K27me3 ChIP-seq data from LPS stimulated macrophages, shows these protective genes, *NFKBIA,*
413 *NFKBIE,* and *TIRAP*, are also associated with KDM6B and/or H3K27me3, whilst NEMO and IRAK4 are not
414 [20]. Since *NFKBIA,* and *NFKBIE* are known to inhibit NF-κB through sequestration within the cytoplasm
415 [15,69,70], one could hypothesize KDM6B is a chromatin level negative regulator that balances inflammatory
416 signaling in conjunction with p65 across a unique "p65-KDM6B" axis. In this context, KDM6B serves as the
417 molecular "regulator or brake" responsible for modulating the host response based upon the severity, or
418 degree of inflammatory signal input. Interestingly, we found when IL-1β was used to stimulate epithelial
419 cells pretreated with GSK-J4, to inhibit KDM6B activity, there was a significant loss of the *RelB* transcript,
420 a known negative mediator of RelA [47]. How KDM6B influences *RelB* transcription is unknown. Further

421 support for KDM6B as an inflammatory regulator is evidenced by our *in vivo* studies showing chemical
422 inhibition of KDM6B dampens the ability of the murine host to control TIGR4 infection and the escape of
423 an otherwise confined serotype 6B isolate from the murine nasal cavity.

424 Overall, our data demonstrates the first biological role of KDM6B in moderating the host response
425 to bacteria. We further reveal catalytically active KDM6B is required for host-mediated tolerogenic
426 confinement of a 6B ST90 (CC156 lineage F) strain within a murine model of infection. We further show
427 exogenous addition of IL-11, in the same murine model, to promote confinement of an otherwise lethal
428 infection with a TIGR4 strain. Future studies characterizing the molecular interplay of chromatin and
429 cellular processes across the spectrum of pneumococcal host responses will not only identify new means
430 to combat pneumococcal disease, but may also reveal the processes exploited by commensal organisms
431 as well.

432

433

434 **Materials and Methods**:

435 Bacterial strains, growth conditions and CFU enumeration. Clinical isolates of serotypes 6B (ST90; CNRP#
436 43494), 19A (ST276; CNRP# 45426) and 1 (non-hemolytic; ST306; CNRP# 43810) were obtained from the
437 Centre National de Référence des Pneumocoques (Emmanuelle Varon; Paris, France). Serotype 19F
438 (BHN100; ST162 Birgitta Henriques Normark, Karolinska Institutet [59]), serotype 4 TIGR4 (Thomas Kohler,
439 Universität Greifswald), and serotype 1 (ST304 hemolytic; M. Mustapha Si-Tahar, Université de Tours).
440 Experimental starters were prepared from frozen master stocks struck on 5% Columbia blood agar plates
441 (Biomerieux Ref# 43041) and grown overnight at 37°C with 5% CO_2 prior to outgrowth in Todd-Hewitt
442 (BD) broth supplemented with 50 mM HEPES (Sigma) (TH+H) at 37°C with 5% CO_2 in closed falcon tubes.
443 Midlog bacteria were pelleted, and diluted to 0.6 OD_{600} /mL in TH+H media supplemented with Luria-
444 Bertani (BD) and 15% glycerol final concentration. Aliquots were made and frozen at -80°C for
445 experiments. All experiments were performed with frozen experimental starters of *S. pneumoniae* less
446 than 14 days old. For experiments, starters were grown to midlog phase in TH+H broth at 37°C with 5%
447 CO_2 in closed falcon tubes, pelleted at 1,500xg for 10 mins at room temperature (RT), washed in DPBS,
448 and concentrated in 1mL DPBS prior to dilution at desired CFU/mL using 0.6 OD_{600} /mL conversion factors
449 in either cell culture media or DPBS for animal studies (conversion factors Sup. Table 4). For
450 paraformaldehyde (PFA) killed bacteria the concentrated bacteria, prior to dilution, was incubated 4% PFA
451 for 30 mins at RT, washed in DPBS, and diluted to desired CFU/mL using 0.6 OD_{600} /mL conversion factors.
452 Bacteria CFU enumeration was determined by serial dilution plating on 5% Columbia blood agar plates.
453

454 Cell culture and *In vitro* challenge. A549 human epithelial cells (ATCC ref# CCL-185) were maintained in
455 F12K media (Gibco) supplemented with 1x GlutaMax (Gibco) and 10% heat inactivated fetal calf serum
456 (FCS) at 37°C with 5% CO_2. Detroit 562 nasopharyngeal epithelial cells (ATCC ref# CCL-138) and BEAS-2B
457 epithelial cells (ATCC ref# CRL-9609) were maintained in DMEM supplemented with 1x sodium pyruvate
458 (Gibco) and 1x GlutaMax (Gibco) 10% heat inactivated FCS. Stable HeLa GFP-p65 were generated using
459 the transposon-based sleeping beauty system, and maintained in DMEM supplemented with 1x sodium
460 pyruvate (Gibco), 1x GlutaMax (Gibco) and 10% heat inactivated FCS [71]. A549, BEAS-2B, Detroit 562 or
461 HeLa GFP-p65 cells were used until passage 15. For *in vitro* challenge studies, A549, BEAS-2B, Detroit 562,
462 or HeLa GFP-p65 cells were plated in tissue culture treated plates at $2x10^5$ cells (6well; for 72 hrs), $5x10^4$
463 cells (24well; for 48 hrs), or $1x10^4$ cells (96well; for 48 hrs). Cells were used at 90% confluency for all *in*
464 *vitro* studies. Bacterial inoculums diluted in cell culture media were added to cells, and bacterial-epithelial
465 cell contact synchronized by centrifugation at 200xg for 10 mins at RT, then moved to 37°C with 5% CO_2

466 for 2 hrs. For inhibitor studies, cell culture media was aspirated, and replaced with filter sterilized culture
467 media containing inhibitor volume matched DMSO (Sigma), GSK-J4 (Sigma ref# SML0701), or BAY 11-7082
468 (Sigma ref# B5556) at 10 µM final concentration for 24 hrs or 3 hrs respectively prior to bacterial addition.
469 Human IL-11 (Miltenyi Biotec ref# 130-094-623) and human IL-1β (Enzo Life Sciences ref# ALX-522-056)
470 were used at 100 ng/mL and 10 ng/mL final concentration respectively in cell culture media.
471
472 Immunofluorescence and Trypan blue bright field microscopy. To quantify nuclear KDM6B, A549 cells
473 were seeded on acid washed and UV treated coverslips in 24well plates as described above, 2 hrs post-
474 challenge media was aspirated, cells washed in DPBS, and fixed with 2.5% PFA for 10 mins at RT. Coverslips
475 were blocked and permeabilized overnight in 5% BSA 0.5% Tween20. Coverslips were incubated for 1hr
476 at RT with KDM6B (1:500; abcam ref# ab38113) diluted in 5% BSA 0.5% Tween20, washed three times in
477 0.5% Tween20, and incubated for 1 hr with Alexa Fluor 488 secondary. After secondary, coverslips were
478 washed three times in 0.5% Tween20 and mounted using Prolong Gold with DAPI (Invitrogen). Confocal
479 microscopy images were acquired on a Zeiss axio observer spinning disk confocal. Nuclear KDM6B
480 intensity per cell was quantified within an ROI generated from the DAPI signal in Fiji [72]. For Trypan
481 exclusion microscopy, A549 cells were seeded in 96well plates as described above. 2 hrs post-challenge
482 culture media was aspirated, cells washed in DPBS, and Trypan blue (Thermo) added for 10 mins at RT.
483 Trypan blue was removed, and cells fixed with 2.5% PFA for 10mins at RT. PFA was removed and fixed
484 cells washed in DPBS prior to imaging on a EVOS FL (Thermo). Trypan positive cells were scored manually
485 as % of total cells in an imaged field.
486
487 A549 epithelial microarray. A549 cells were infected as described above, and total RNA harvested using
488 RNeasy kit (Qiagen). RNA quality was confirmed using a Bioanalyzer (Agilent). Affymetrix GeneChip human
489 transcriptome array 2.0 was processed as per manufacturer's instructions. Data was analyzed using TAC
490 4.0 (Applied Biosystems).
491
492 LDH assay. LDH assays were performed on cell culture supernatants as per manufacturer's instructions
493 (Pierce LDH cytotoxicity kit ref# 88953). LDH absorbance was read using Cytation 5 (BioTek) at
494 manufacturer's recommended excitation and emissions.
495
496 ChIP and ChIP-qPCR. Detailed ChIP buffer components are in supplemental methods. In brief, $8x10^6$ A549
497 cells were cross-linked in tissue culture plates with 1% formaldehyde for 10 mins at RT, then quenched

498 with 130 mM glycine for 5 mins at RT. Cells were washed in DPBS, gently scraped, and transferred to an
499 eppendorf. Harvested cells were pelleted at 200xg, supernatant aspirated and frozen -20°C. To obtain
500 chromatin, cell pellets were thawed on ice and lysed for 30 mins on ice in nuclear isolation buffer
501 supplemented with 0.2% Triton X-100. Nuclei pelleted, supernatant aspirated and suspended in chromatin
502 shearing buffer for sonication (10 cycles of 15 sec 'on' and 30 sec 'off') with a Bioruptor (Diagenode) to
503 200-900bp size. Sheared chromatin was cleared by centrifugation, then sampled for size using 2% agarose
504 gel electrophoresis and quantification using Pico488 (Lumiprobe ref# 42010). ChIP grade antibodies to
505 p65 (L8F6) (CST ref #6956), KDM6B (abcam ref# ab38113), H3K27me3 (abcam ref# ab6002), H3 (abcam
506 ref# ab195277), or H3K27me2 (diagenode ref# C15410046-10) were used at manufacturer's
507 recommended concentrations and bound to DiaMag beads (diagenode ref # C03010021-150) overnight
508 with gentle rotation. Quantified chromatin was diluted to 10 µg per immunoprecipitation condition was
509 added to antibody bound DiaMag beads overnight with gentle rotation with 8% of input reserved. Beads
510 were washed with buffers 1-6 (supplemental methods), decrosslinked by boiling for 10 mins with 10%
511 Chelex, treated with RNase and proteinase K, then purified using phenol-chloroform extraction followed
512 by isopropanol precipitation. Recovered DNA was suspend in molecular grade water, and 1 µL used for
513 Sybr Green reactions as per manufacturer's instructions on a BioRad CFX384 (BioRad). % recovery was
514 calculated as 2 raised to the adjusted input Ct minus IP Ct multiplied by 100. For histone marks,
515 H3K27me3/2, the % recovery was normalized to the % recovery of H3. ChIP qPCR primers listed in Sup.
516 Table 4.
517
518 RNA isolation and RT-PCR. Total RNA isolated using TRIzol (Life technologies ref#15596-026) extraction
519 method as per manufacturer's recommendations. Recovered RNA was suspended in molecular grade
520 water, nano dropped and 5 µg converted to cDNA using Super Script IV as per manufacturer's instructions.
521 cDNA was diluted to 20 ng/µL in molecular grade water and 1 µL used for Sybr Green reactions in technical
522 duplicate or triplicate as per manufacturer's instructions on a BioRad CFX384 (BioRad). RT-PCR primers
523 listed in Sup. Table 4. Relative expression was calculated by ΔΔCt method to *GapDH* [73].
524
525 Immunoblots and quantification. Cell culture media was removed, cells were washed in DPBS and whole
526 cell lysates harvested with Laemmli buffer [74]. Lysates were boiled 10min, and frozen at -20°C. Whole cell
527 lysates were ran on 8% polyacrylamide SDS PAGE gels, transferred to PVDF membrane (BioRad TransBlot),
528 blocked 1 hr in 5% BSA TBST, then probed for p65 (CST ref #6956), p65 phosphorylation at serine 536 (CST
529 ref# 3033), or actin AC-15 monoclonal (Sigma ref# A5441) as per manufacturer's recommendations.

530 Appropriate secondary-HRP conjugated antibodies were used with clarity ECL (BioRad) developing
531 reagents. Membranes were developed on ChemiDoc Touch (BioRad).
532
533 *In vivo* animal studies. All protocols for animal experiments were reviewed and approved by the CETEA
534 (Comité d'Ethique pour l'Expérimentation Animale - Ethics Committee for Animal Experimentation) of the
535 Institut Pasteur under approval number Dap170005 and were performed in accordance with national laws
536 and institutional guidelines for animal care and use. Wildtype C57BL/6 female 8-9 week old mice were
537 purchased from Janvier Labs (France). Wildtype C57BL/6 male 10-12 week old mice used for survival
538 studies (Institut Pasteur). Animals were anesthetized with a ketamine and xylazine cocktail prior to
539 intranasal challenge with 20 µL of 3 - $4x10^6$ CFU of TIGR4 or 6B. Bacterial inoculums were made as
540 described above with minor modification. In brief, after 0.6 OD_{600} bacterial were concentrated and diluted
541 in either filter sterilized DMSO/DPBS or 5 mM GSK-J4/DPBS. For IL-11 studies, recombinant mouse IL-11
542 (Enzo; ENZ-PRT243-0010) was added to bacterial inoculums to a final concentration of 7,500 ng/mL (0.15
543 ug per mouse). After 24 hrs or 48 hrs post-inoculation animals were euthanized by CO_2 affixation. The
544 nasal lavage was obtained by blocking the oropharynx, to avoid leakage into the oral cavity and lower
545 airway, and nares flushed with 500 µL DPBS. Bronchoalveolar lavage fluid (BALF), lungs, and spleens were
546 collected and placed in 1 mL DPBS supplemented with 2x protease inhibitor cocktail (Sigma ref # P1860).
547 CFU were enumerated as described above on 5 µg/mL Gentamicin Columbia Blood agar selection plates.
548 For survival studies, animals were monitored daily for weight loss and disease signs. Animals were
549 euthanized by CO_2 affixation at ≥20% loss of initial weight or at body conditioning score (BCS) ≤2[75].
550
551 Statistical analysis. All experiments, unless otherwise noted, were biologically repeated 3-4 times with the
552 statistical test in the figure legends. Data normality was tested by Shapiro-Wilk test, and appropriate
553 parametric or non-parametric tests performed. *P* values were calculated using GraphPad Prism software.
554 For RT-PCR all statistics were calculated on either the ΔΔCt or ΔCt depending on the desired comparison.
555 PCA plots using the "prcomp" function of the base stats package in R on scaled and mean centered log_2
556 transformed data, or ΔCt for cross-treatment comparisons. Microscopy data was collected from analysis
557 of 30-100 cells for nuclear staining, or 200-300 cells for brightfield per biological replicate per group. ChIP-
558 qPCR studies used four technical replicates per biological with all data graphed. Animal studies used the
559 minimum number of animals required for power calculated by analysis of CFU using G*Power software.

560 **Supplemental Methods:**

561 Human IL-11 ELISA. Detroit 562 cells were infected with *S. pneumoniae* for 6 hrs, and supernatants were
562 collected for IL-11 analysis using an IL-11 Human Elisa Duo Set (R&D Systems, DY218 lot number 5225707),
563 according to manufacturers' instructions.

564

565 AlamarBlue cytotoxicity. A549 cell viability was determined using AlamarBlue (Thermo ref# DAL1025) as
566 previously described [76]. AlamarBlue absorbance was read using a Cytation 5 (BioTek) at manufacturer's
567 recommended excitation and emissions.

568

569 Crude hemolytic assay. Red blood cells (RBC) from horse blood (Thermo ref# SR0050C) were washed three
570 times in DPBS and suspended at a final concentration of 1% v/v, with 100 µl moved to individual wells of
571 a 96well U-bottom plate and stored at 4°C until use. Cell culture supernatants were collected from
572 infected A549 cells 2 hrs post-infection, centrifuged and filtered prior to 100 µl being combined with RBCs.
573 For positive lysis control, volume matched water and 2% triton-X100 were used, the negative control was
574 RBCs with cell culture media alone. The plate was incubated for 30 mins at 37 °C with 5% CO_2, then
575 centrifuged 5 mins at 200xg. Supernatants (100 µl) were transferred to a new clear 96well plate and
576 absorbance (OD_{540}) read using Cytation 5 (BioTek). % Lysis was calculated as absorbance of sample
577 adjusted for media alone over positive lysis sample adjusted for media alone multiplied by 100.

578

579 Oral commensal *in vitro* infection and RT-PCR. *Streptococcus gordonii*, *S. oralis*, and *S. sanguinis* were all
580 cultivated in brain heart infusion (BHI) broth, *Fusobacterium nucleatum* was grown in BHI broth
581 supplemented with 5 ug/mL hemin and 1 ug/mL menadione, and *Eikenella corrodens* was grown in TYGVS
582 broth. All bacteria were cultured anaerobically until midlog phase. Human telomerase immortalized
583 gingival keratinocytes (TIGK) were maintained at 37 °C with 5% CO_2 in Dermalife-K serum-free culture
584 medium (Lifeline Cell Technology)[77]. Epithelial cells at 80% confluency were challenged with the different
585 bacteria species at an MOI of 100 for 3 hrs, were washed and fresh media was added for another 18 hrs.
586 Total RNA was isolated using the Qiagen RNeasy mini kit (Qiagen). RNA concentrations were determined
587 spectrophotometrically using a NanoDrop 2000 and quality was determined using the Qubit 4 fluorimeter.
588 cDNA from total RNA was synthesized (500 ng RNA per reaction volume) using a High Capacity cDNA
589 reverse transcription kit (Applied Biosystems). qRT-PCR was performed using *IL-11* and *GAPDH* primers in
590 Sup. Table 4. qRT-PCR was performed on an Applied Biosystems QuantStudio 3 cycler and the auto-
591 calculated threshold cycle selected. The cycle threshold (Ct) values were determined, and mRNA

592 expression levels were normalized to *GAPDH* and expressed relative to controls following the 2−ΔΔCT
593 method.
594
595 Pneumococcus growth curve with recombinant murine IL-11. Midlog bacterial inoculums for both TIGR4
596 and TIGR4 supplemented with IL-11, as described under "*In vivo* animal studies", were used for growth
597 analysis with the final dilution being in TH+H. Bacterial aliquots (100µl each) were distributed into wells
598 of a clear 96well plate. Plates were incubated at 37°C with 5% CO_2 for 2 hrs, and absorbance (OD_{600}) taken
599 at 20 min intervals using a Cytation5 (BioTek). Absorbance was calculated after normalizing to TH+H
600 growth media alone.
601
602 ChIP buffer solutions as follows:

Nuclear Isolation Buffer (NIB)	Chromatin shearing buffer (Buffer C)	SDS dilution buffer (buffer D)
15mM Tris pH 7.5	1% SDS	0.6% Triton X-100
60mM KCl	10mM Tris HCL pH 8.0	0.06% NaDOC
15mM $NaCl_2$	1mM EDTA	150mM NaCl
250mM sucrose	0.5mM EGTA	12mM Tris HCL pH 8.0
1mM $CaCl_2$		1mM EDTA
5mM $MgCl_2$		0.5mM EGTA
Day of use	Day of use	Day of use
1x PhosSTOP	1x PhosSTOP	1x PhosSTOP
10mM Sodium Butyrate	10mM Sodium Butyrate	10mM Sodium Butyrate
0.2mM PMSF	0.2mM PMSF	0.2mM PMSF
1x protease cocktail	1x protease cocktail	1x protease cocktail
1x phosphatase inhibitor cocktail	1x phosphatase inhibitor cocktail	1x phosphatase inhibitor cocktail

603

10% Chelex	1.25M pH 7.6 Glycine buffer
10g into 100mL miliQ water	46.91g Glycine in 400mL milliQ water
	pH adjusted to 7.6 and QC to 500mL

604
605

Wash buffer 1 (isotonic)	Wash buffer 2 (isotonic, ionic charge change)	Wash buffer 3 (high salt dilution)
1% Triton X-100	0.5% NP40	0.7% Triton X-100
0.1% NaDOC	0.5% Triton X-100	0.1% NaDOC
150mM NaC	0.5% NaDOC	250mM NaCl
10mM Tris HCL pH 8.0	150mM NaCl	10mM Tris HCL pH 8.0
	10mM Tris HCL pH 8.0	
Wash buffer 4 (high salt dilution)	Wash buffer 5 (salt dilution)	Wash buffer 6 (TE)
0.5% NP40	0.1% NP40	20mM Tris HCL pH 8.0
0.5% Triton X-100	150mM NaCl	1mM EDTA
250mM LiCl	20mM Tris HCL pH 8.0	

20mM Tris HCL pH 8.0	1mM EDTA	
1mM EDTA		

606

607 **References:**

608 1 Donkor, E. S. Understanding the pneumococcus: transmission and evolution. *Frontiers in cellular*
609 *and infection microbiology* **3**, 7-7, doi:10.3389/fcimb.2013.00007 (2013).
610 2 Shak, J. R., Vidal, J. E. & Klugman, K. P. Influence of bacterial interactions on pneumococcal
611 colonization of the nasopharynx. *Trends in microbiology* **21**, 129-135,
612 doi:10.1016/j.tim.2012.11.005 (2013).
613 3 Weiser, J. N., Ferreira, D. M. & Paton, J. C. Streptococcus pneumoniae: transmission, colonization
614 and invasion. *Nature reviews. Microbiology* **16**, 355-367, doi:10.1038/s41579-018-0001-8 (2018).
615 4 Pneumococcal vaccines WHO position paper--2012. *Releve epidemiologique hebdomadaire* **87**,
616 129-144 (2012).
617 5 Bogaert, D., De Groot, R. & Hermans, P. W. Streptococcus pneumoniae colonisation: the key to
618 pneumococcal disease. *Lancet Infect Dis* **4**, 144-154, doi:10.1016/s1473-3099(04)00938-7 (2004).
619 6 Henriques-Normark, B., Blomberg, C., Dagerhamn, J., Battig, P. & Normark, S. The rise and fall of
620 bacterial clones: Streptococcus pneumoniae. *Nat Rev Micro* **6**, 827-837 (2008).
621 7 Prevention, U. S. D. o. H. a. H. S. C. f. D. C. a. (ed U.S. Department of Health and Human Services
622 & Centers for Disease Control and Prevention) 114 (CDC, CDC, 2013).
623 8 Ferreira, D. M. *et al.* Controlled human infection and rechallenge with Streptococcus pneumoniae
624 reveals the protective efficacy of carriage in healthy adults. *American journal of respiratory and*
625 *critical care medicine* **187**, 855-864, doi:10.1164/rccm.201212-2277OC (2013).
626 9 Weiser, J. N. The pneumococcus: why a commensal misbehaves. *Journal of molecular medicine*
627 *(Berlin, Germany)* **88**, 97-102, doi:10.1007/s00109-009-0557-x (2010).
628 10 Henriques-Normark, B. & Tuomanen, E. I. The Pneumococcus: Epidemiology, Microbiology, and
629 Pathogenesis. *Cold Spring Harbor perspectives in medicine* **3**, a010215,
630 doi:10.1101/cshperspect.a010215 (2013).
631 11 Jochems, S. P., Weiser, J. N., Malley, R. & Ferreira, D. M. The immunological mechanisms that
632 control pneumococcal carriage. *PLoS pathogens* **13**, e1006665-e1006665,
633 doi:10.1371/journal.ppat.1006665 (2017).
634 12 Robson, R. L., Reed, N. A. & Horvat, R. T. Differential activation of inflammatory pathways in A549
635 type II pneumocytes by Streptococcus pneumoniae strains with different adherence properties.
636 *BMC infectious diseases* **6**, 71, doi:10.1186/1471-2334-6-71 (2006).
637 13 Weight, C. M. *et al.* Microinvasion by Streptococcus pneumoniae induces epithelial innate
638 immunity during colonisation at the human mucosal surface. *Nature communications* **10**, 3060,
639 doi:10.1038/s41467-019-11005-2 (2019).
640 14 Quinton, L. J. & Mizgerd, J. P. Dynamics of lung defense in pneumonia: resistance, resilience, and
641 remodeling. *Annual review of physiology* **77**, 407-430, doi:10.1146/annurev-physiol-021014-
642 071937 (2015).
643 15 Ghosh, S. & Hayden, M. S. New regulators of NF-kappaB in inflammation. *Nature reviews.*
644 *Immunology* **8**, 837-848, doi:10.1038/nri2423 (2008).
645 16 Bhatt, D. & Ghosh, S. Regulation of the NF-kappaB-Mediated Transcription of Inflammatory
646 Genes. *Frontiers in immunology* **5**, 71, doi:10.3389/fimmu.2014.00071 (2014).
647 17 Dong, J., Jimi, E., Zhong, H., Hayden, M. S. & Ghosh, S. Repression of gene expression by
648 unphosphorylated NF-kappaB p65 through epigenetic mechanisms. *Genes & development* **22**,
649 1159-1173, doi:10.1101/gad.1657408 (2008).
650 18 Fujioka, S. *et al.* NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation
651 of AP-1 activity. *Molecular and cellular biology* **24**, 7806-7819, doi:10.1128/MCB.24.17.7806-
652 7819.2004 (2004).

653 19 Das, N. D., Jung, K. H. & Chai, Y. G. The role of NF-kappaB and H3K27me3 demethylase, Jmjd3, on
654 the anthrax lethal toxin tolerance of RAW 264.7 cells. *PloS one* **5**, e9913,
655 doi:10.1371/journal.pone.0009913 (2010).
656 20 De Santa, F. *et al.* Jmjd3 contributes to the control of gene expression in LPS-activated
657 macrophages. *Embo J* **28**, 3341-3352, doi:10.1038/emboj.2009.271 (2009).
658 21 De Santa, F. *et al.* The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of
659 polycomb-mediated gene silencing. *Cell* **130**, 1083-1094, doi:10.1016/j.cell.2007.08.019 (2007).
660 22 Na, J. *et al.* Histone H3K27 Demethylase JMJD3 in Cooperation with NF-κB Regulates Keratinocyte
661 Wound Healing. *Journal of Investigative Dermatology* **136**, 847-858,
662 doi:https://doi.org/10.1016/j.jid.2015.11.029 (2016).
663 23 Salminen, A., Kaarniranta, K., Hiltunen, M. & Kauppinen, A. Histone demethylase Jumonji D3
664 (JMJD3/KDM6B) at the nexus of epigenetic regulation of inflammation and the aging process.
665 *Journal of molecular medicine (Berlin, Germany)* **92**, 1035-1043, doi:10.1007/s00109-014-1182-x
666 (2014).
667 24 Diermeier, S. *et al.* TNFα signalling primes chromatin for NF-κB binding and induces rapid and
668 widespread nucleosome repositioning. *Genome biology* **15**, 536, doi:10.1186/s13059-014-0536-6
669 (2014).
670 25 Lone, I. N. *et al.* Binding of NF-κB to Nucleosomes: Effect of Translational Positioning, Nucleosome
671 Remodeling and Linker Histone H1. *PLoS genetics* **9**, e1003830,
672 doi:10.1371/journal.pgen.1003830 (2013).
673 26 Christian, F., Smith, E. L. & Carmody, R. J. The Regulation of NF-κB Subunits by Phosphorylation.
674 *Cells* **5**, 12, doi:10.3390/cells5010012 (2016).
675 27 Oeckinghaus, A. & Ghosh, S. The NF-κB Family of Transcription Factors and Its Regulation. *Cold*
676 *Spring Harbor perspectives in biology* **1**, a000034, doi:10.1101/cshperspect.a000034 (2009).
677 28 Wong, D. *et al.* Extensive characterization of NF-κB binding uncovers non-canonical motifs and
678 advances the interpretation of genetic functional traits. *Genome biology* **12**, R70-R70,
679 doi:10.1186/gb-2011-12-7-r70 (2011).
680 29 Avvakumov, N., Nourani, A. & Côté, J. Histone Chaperones: Modulators of Chromatin Marks.
681 *Molecular cell* **41**, 502-514, doi:https://doi.org/10.1016/j.molcel.2011.02.013 (2011).
682 30 Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. *Cell research*
683 **21**, 381-395, doi:10.1038/cr.2011.22 (2011).
684 31 Black, J. C. & Whetstine, J. R. Chromatin landscape: Methylation beyond transcription. *Epigenetics*
685 **6**, 13-19, doi:10.4161/epi.6.1.13331 (2011).
686 32 Hammond, C. M., Stromme, C. B., Huang, H., Patel, D. J. & Groth, A. Histone chaperone networks
687 shaping chromatin function. *Nature reviews. Molecular cell biology* **18**, 141-158,
688 doi:10.1038/nrm.2016.159 (2017).
689 33 Kouzarides, T. Chromatin modifications and their function. *Cell* **128**, 693-705,
690 doi:10.1016/j.cell.2007.02.005 (2007).
691 34 Lorch, Y. & Kornberg, R. D. Chromatin-remodeling and the initiation of transcription. *Quarterly*
692 *reviews of biophysics* **48**, 465-470, doi:10.1017/s0033583515000116 (2015).
693 35 Markolovic, S. *et al.* Structure–function relationships of human JmjC oxygenases—demethylases
694 versus hydroxylases. *Current Opinion in Structural Biology* **41**, 62-72,
695 doi:https://doi.org/10.1016/j.sbi.2016.05.013 (2016).
696 36 Burchfield, J. S., Li, Q., Wang, H. Y. & Wang, R.-F. JMJD3 as an epigenetic regulator in development
697 and disease. *The international journal of biochemistry & cell biology* **67**, 148-157,
698 doi:10.1016/j.biocel.2015.07.006 (2015).

699 37 Hong, S. *et al.* Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27
700 demethylases. *Proceedings of the National Academy of Sciences of the United States of America*
701 **104**, 18439-18444, doi:10.1073/pnas.0707292104 (2007).
702 38 Xiang, Y. *et al.* JMJD3 is a histone H3K27 demethylase. *Cell research* **17**, 850-857,
703 doi:10.1038/cr.2007.83 (2007).
704 39 Satoh, T. *et al.* The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses
705 against helminth infection. *Nature immunology* **11**, 936-944, doi:10.1038/ni.1920 (2010).
706 40 Chao, Y. & Zhang, T. Optimization of fixation methods for observation of bacterial cell morphology
707 and surface ultrastructures by atomic force microscopy. *Applied microbiology and biotechnology*
708 **92**, 381-392, doi:10.1007/s00253-011-3551-5 (2011).
709 41 Pierce, J. W. *et al.* Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and
710 endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. *The Journal*
711 *of biological chemistry* **272**, 21096-21103 (1997).
712 42 Karin, M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. *The Journal of*
713 *biological chemistry* **274**, 27339-27342 (1999).
714 43 Gilmore, T. D. The Rel/NF-kappaB signal transduction pathway: introduction. *Oncogene* **18**, 6842-
715 6844, doi:10.1038/sj.onc.1203237 (1999).
716 44 Kruidenier, L. *et al.* A selective jumonji H3K27 demethylase inhibitor modulates the
717 proinflammatory macrophage response. *Nature* **488**, 404, doi:10.1038/nature11262
718 https://www.nature.com/articles/nature11262#supplementary-information (2012).
719 45 Wingender, E. Compilation of transcription regulating proteins. *Nucleic acids research* **16**, 1879-
720 1902, doi:10.1093/nar/16.5.1879 (1988).
721 46 Agger, K. *et al.* UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation
722 and development. *Nature* **449**, 731-734, doi:10.1038/nature06145 (2007).
723 47 Millet, P., McCall, C. & Yoza, B. RelB: an outlier in leukocyte biology. *Journal of leukocyte biology*
724 **94**, 941-951, doi:10.1189/jlb.0513305 (2013).
725 48 Kadioglu, A., Weiser, J. N., Paton, J. C. & Andrew, P. W. The role of Streptococcus pneumoniae
726 virulence factors in host respiratory colonization and disease. *Nature reviews. Microbiology* **6**,
727 288-301, doi:10.1038/nrmicro1871 (2008).
728 49 Walev, I. *et al.* Resealing of large transmembrane pores produced by streptolysin O in nucleated
729 cells is accompanied by NF-kappaB activation and downstream events. *FASEB journal : official*
730 *publication of the Federation of American Societies for Experimental Biology* **16**, 237-239,
731 doi:10.1096/fj.01-0572fje (2002).
732 50 Tran, S.-L., Puhar, A., Ngo-Camus, M. & Ramarao, N. Trypan blue dye enters viable cells incubated
733 with the pore-forming toxin HlyII of Bacillus cereus. *PloS one* **6**, e22876-e22876,
734 doi:10.1371/journal.pone.0022876 (2011).
735 51 Elias, J. A. *et al.* Epithelial interleukin-11. Regulation by cytokines, respiratory syncytial virus, and
736 retinoic acid. *The Journal of biological chemistry* **269**, 22261-22268 (1994).
737 52 Du, X. & Williams, D. A. Interleukin-11: Review of Molecular, Cell Biology, and Clinical Use. *Blood*
738 **89**, 3897-3908 (1997).
739 53 Traber, K. E. *et al.* Roles of interleukin-11 during acute bacterial pneumonia. *PloS one* **14**,
740 e0221029-e0221029, doi:10.1371/journal.pone.0221029 (2019).
741 54 Yap, J., Foo, C. F. H., Lee, M. Y., Stanton, P. G. & Dimitriadis, E. Proteomic analysis identifies
742 interleukin 11 regulated plasma membrane proteins in human endometrial epithelial cells in vitro.
743 *Reprod Biol Endocrinol* **9**, 73-73, doi:10.1186/1477-7827-9-73 (2011).

744 55 Han, Y. *et al.* Repairing effects of interleukin 11 (IL-11) towards high dose methotrexate-induced
745 rat small intestinal mucositis and its impacts on T-lymphoblastic leukemia cell line. *Iran J Basic*
746 *Med Sci* **19**, 837-843 (2016).
747 56 Lee, C. G. *et al.* Endogenous IL-11 signaling is essential in Th2- and IL-13-induced inflammation
748 and mucus production. *American journal of respiratory cell and molecular biology* **39**, 739-746,
749 doi:10.1165/rcmb.2008-0053OC (2008).
750 57 Wen, C.-Y. *et al.* IL-11 up-regulates Tie-2 expression during the healing of gastric ulcers in rats.
751 *World journal of gastroenterology* **9**, 788-790, doi:10.3748/wjg.v9.i4.788 (2003).
752 58 Orazi, A., Du, X., Yang, Z., Kashai, M. & Williams, D. A. Interleukin-11 prevents apoptosis and
753 accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and
754 radiation. *Laboratory investigation; a journal of technical methods and pathology* **75**, 33-42
755 (1996).
756 59 Sandgren, A. *et al.* Virulence in mice of pneumococcal clonal types with known invasive disease
757 potential in humans. *The Journal of infectious diseases* **192**, 791-800, doi:10.1086/432513 (2005).
758 60 Ohguchi, H. *et al.* KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and
759 survival. *Leukemia* **31**, 2661, doi:10.1038/leu.2017.141

760 https://www.nature.com/articles/leu2017141#supplementary-information (2017).
761 61 Chen, S. *et al.* The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting
762 transcriptional elongation. *Genes & development* **26**, 1364-1375, doi:10.1101/gad.186056.111
763 (2012).
764 62 Young, M. D. *et al.* ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with
765 transcriptional activity. *Nucleic acids research* **39**, 7415-7427, doi:10.1093/nar/gkr416 (2011).
766 63 Zafar, M. A., Wang, Y., Hamaguchi, S. & Weiser, J. N. Host-to-Host Transmission of Streptococcus
767 pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. *Cell host & microbe* **21**, 73-83,
768 doi:10.1016/j.chom.2016.12.005 (2017).
769 64 Nishina, T. *et al.* Interleukin-11 links oxidative stress and compensatory proliferation. *Sci Signal* **5**,
770 ra5, doi:10.1126/scisignal.2002056 (2012).
771 65 Mahboubi, K., Biedermann, B. C., Carroll, J. M. & Pober, J. S. IL-11 Activates Human Endothelial
772 Cells to Resist Immune-Mediated Injury. *The Journal of Immunology* **164**, 3837-3846,
773 doi:10.4049/jimmunol.164.7.3837 (2000).
774 66 Moreno, R., Sobotzik, J.-M., Schultz, C. & Schmitz, M. L. Specification of the NF-κB transcriptional
775 response by p65 phosphorylation and TNF-induced nuclear translocation of IKKε. *Nucleic acids*
776 *research* **38**, 6029-6044, doi:10.1093/nar/gkq439 (2010).
777 67 Collins, P. E., Mitxitorena, I. & Carmody, R. J. The Ubiquitination of NF-κB Subunits in the Control
778 of Transcription. *Cells* **5**, 23, doi:10.3390/cells5020023 (2016).
779 68 Brouwer, M. C. *et al.* Host genetic susceptibility to pneumococcal and meningococcal disease: a
780 systematic review and meta-analysis. *Lancet Infect Dis* **9**, 31-44, doi:10.1016/s1473-
781 3099(08)70261-5 (2009).
782 69 Li, Z. & Nabel, G. J. A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA
783 (p65)-mediated NF-kappaB transcription. *Molecular and cellular biology* **17**, 6184-6190,
784 doi:10.1128/mcb.17.10.6184 (1997).
785 70 Scherer, D. C., Brockman, J. A., Chen, Z., Maniatis, T. & Ballard, D. W. Signal-induced degradation
786 of I kappa B alpha requires site-specific ubiquitination. *Proceedings of the National Academy of*
787 *Sciences of the United States of America* **92**, 11259-11263, doi:10.1073/pnas.92.24.11259 (1995).
788 71 Kowarz, E., Loscher, D. & Marschalek, R. Optimized Sleeping Beauty transposons rapidly generate
789 stable transgenic cell lines. *Biotechnology journal* **10**, 647-653, doi:10.1002/biot.201400821
790 (2015).

791 72 Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nature methods* **9**,
792 676-682, doi:10.1038/nmeth.2019 (2012).
793 73 Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time
794 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods (San Diego, Calif.)* **25**, 402-408,
795 doi:10.1006/meth.2001.1262 (2001).
796 74 Laemmli, U. K. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage
797 T4. *Nature* **227**, 680-685, doi:10.1038/227680a0 (1970).
798 75 Ullman-Cullere, M. H. & Foltz, C. J. Body condition scoring: a rapid and accurate method for
799 assessing health status in mice. *Laboratory animal science* **49**, 319-323 (1999).
800 76 Connor, M. G. *et al.* Yersinia pestis Targets the Host Endosome Recycling Pathway during the
801 Biogenesis of the Yersinia Containing Vacuole To Avoid Killing by Macrophages. *mBio* **9**, e01800-
802 01817, doi:10.1128/mBio.01800-17 (2018).
803 77 Moffatt-Jauregui, C. E. *et al.* Establishment and characterization of a telomerase immortalized
804 human gingival epithelial cell line. *J Periodontal Res* **48**, 713-721, doi:10.1111/jre.12059 (2013).

805
806

807 **Author Contributions:**

808 Conceived and designed all experiments: MGC and MAH. Performed experiments: MGC; EP
809 (KDM6B microscopy and HeLa GFP-p65 western blot); TC and OR (animal studies); CMW (IL-11 ELISA);
810 DPM and RJL performed all oral commensal infections and RT-PCR. Analyzed data: MGC. LB generated the
811 stable HeLa GFP-p65 cell line under the supervision of JE. MGC wrote the original manuscript draft. MGC
812 and MAH edited and reviewed the manuscript. MAH supervised the research. All authors approved the
813 final manuscript.

814

815 **Acknowledgments:**

816 We would like to thank Emmanuelle Varon, Birgitta Henriques Normark, M. Mustapha Si-Tahar,
817 and Thomas Kohler for their generous gifts of *S. pneumonie* strains. We are thankfully Gregory Dore
818 (Institut Pasteur) for processing the microarray Affymetrix GeneChips. Biostatistics and R discussions with
819 Jose Nabuco (Institute Pasteur) and Jeremy Camp (University of Veterinary Medicine Vienna) were greatly
820 appreciated. Michael G. Connor is supported by the Pasteur Foundation Fellowship. T.M.-N.C. is
821 supported by a fellowship from the Foundation for Medical Research (Mariane Josso Prize), and a
822 donation from Credit Agricole. Melanie Hamon, G5 Chromatin and infection, is supported by the Institut
823 Pasteur, and the Agence National de la Recherche (ANREpiBActIn). Caroline M. Weight was supported by
824 the Medical Research Council (MR/T016329/1). We would like to thank Robert S. Heyderman (UCL) for in
825 depth discussion on the manuscript and is supported by the MRC (MR/T016329/1). Jost Enninga and Laura
826 Barrio, members of Dynamics of host-pathogen interactions unit (Institut Pasteur), are supported by the
827 European Commission (ERC-CoG-Endosubvert), the ANR-HBPsensing, and are members of the IBEID and
828 Milieu Interieur LabExes. Richard J. Lamont is funded by NIH/NIDCR DE01111, DE012505, DE017921 and
829 DE023193.

830

831 **Conflict of interest statement:**

832 The authors declare no conflict of interest.

833

834 **Figure Legends and Tables:**

835 **Figure 1:** *Inflammatory signature of serotype 6B ST90 CC156 lineage F strain*. C57B6 mice (8-9weeks) were
836 challenged intranasally with TIGR4 (3 - 4x10^6 CFU; n=8), 6B (3 - 4x10^6 CFU; n=6), or 6B (3 - 4x10^7 CFU; n=6).
837 Survival and weight monitored for 14 days post-infection. A) Percent survival curve. Mantel-Cox test for
838 significance, ***= pV≤0.001. "= animal euthanized but did not succumb to disease. B) Percent initial body
839 weight. Solid lines per group are Std. Dashed line indicates 20% weight loss threshold. C) RT-PCR validation
840 of inflammatory genes from cells collected 2 hrs post-challenge with either TIGR4 (MOI 20) or 6B (MO20).
841 Heat map represents fold change to uninfected condition (n=5). Multiple T-Test 6B to TIGR4 with
842 significant genes in red. D) Principal component analysis of inflammatory RT-PCR panel (n=5) comparing
843 IL-1β (red), TIGR4 (gray) and 6B (blue). Bioplot of the mean centered and log_2 transformed expression
844 data using the first two components and 95% confidence ellipses around each group. E) Quantification of
845 immunofluorescence microscopy of A549 cells 2 hrs post-challenge with either TIGR4 (MOI 20), 6B (MOI
846 20) or paraformaldehyde fixed 6B or TIGR4 (MOI 20) for nuclear staining of KDM6B normalized to DAPI
847 (n=4; 30-100 cells per replicate and group). Violin plots with median denoted in red. One way-ANOVA
848 non-parametric Kruskal-Wallis test with Dunn's multiple comparison post-hoc test, ****= pV≤0.0001.

849

850 **Figure 2:** *Expression of KDM6B and IL-11 is specific to 6B and requires p65 activation*. Immunoblot of stable
851 HeLa p65-GFP expressing cells. Whole cell lysates 2 hrs post-challenge with either IL-1β (10 ng/mL), TIGR4
852 (MOI 20), or 6B (MOI 20) and probed for p65, phosphorylated p65 at Serine 536 and actin. A)
853 Representative image of immunoblot. B) Actin normalized ratio phos-p65 S536 to total p65 (n=7). Dot plot
854 with mean denoted in red. One way-ANOVA with Tukey's multiple comparison post-hoc test, **= pV≤0.01,
855 ***= pV≤0.001. C) Total RNA 2 hrs post-challenge with 6B (MOI 20), TIGR4 (MOI 20) or IL-1β was harvested
856 from A549 cells treated with either 10 µM BAY 11-7082, 10 µM GSK-J4, or DMSO vehicle control (n=4 per
857 group). Transcript levels for *PTGS2, IL-11* and *KDM6B* determined by RT-PCR. Bar graph ± Std. Student's
858 T-Test to untreated, *= pV≤0.05, **= pV≤0.01, ***= pV≤0.001.

859

860 **Figure 3:** *6B induces IL-11 promoter rearrangement*. Chromatin was obtained from untreated (blue) and
861 10 µM GSK-J4 (light blue) treated A549 cells 2 hrs post-challenge with 6B (MOI 20) in comparison to
862 uninfected (untreated white; treated gray). 10 µg chromatin input used for ChIP of p65, KDM6B,
863 H3K27me3 and histone H3 (H3), followed by ChIP-qPCR at locations (P6, P3 & P2) spanning the NF-κB sites
864 upstream of the transcriptional start site (TSS). A) Schematic of IL-11 promoter with ChIP-qPCR primer
865 locations (P6, P3 & P2) and NF-κB sites. B - F) % recovery of input for p65 (B), KDM6B (C), H3K27me3

866 normalized to H3 (D), H3K27me2 normalized to H3 (F), or H3 (E) bound at P6, P3 & P2 in untreated and
867 GSK-J4 treated samples (n=3 untreated; n=3 GSK-J4 treated). Tukey box and whisker plot with dots
868 representing outliers. Student's T-Test comparisons for untreated to GSK-J4 treated or 6B infected to
869 uninfected, *= pV≤0.05, **= pV≤0.01, ***= pV≤0.001, ns=not significant.
870
871 **Figure 4:** *Comparison of GSK-J4 and IL-11 treatment effects upon the host response to 6B and TIGR4*. A549
872 cells untreated or treated with 10 µM GSK-J4 or 100 ng/mL recombinant human IL-11 prior to 2 hr
873 challenge with either TIGR4 or 6B. Total RNA was harvested and RT-PCR completed for 41 inflammatory
874 genes. Heat mapped expression of A) 6B (MOI 20) challenged cells ± GSK-J4 (n=5), or heat mapped
875 expression of B) TIGR4 (MOI 20) challenged cells ± IL-11 (n=4) to their respected uninfected condition.
876 Multiple T-Test 6B to treatment and TIGR4 to treatment with significant genes highlighted in red. Principal
877 component analysis of inflammatory RT-PCR panel using ΔCt comparing either C) TIGR4 (gray; n=5), 6B +
878 10 µM GSK-J4 (blue; n=5) and uninfected (n=5) or D) TIGR4 + 100 ng/mL IL-11 (gray; n=4), 6B (blue; n=5)
879 and uninfected (n=5). Bioplot of the mean centered ΔCt data using the first two components and 60%
880 concentration ellipses around each group.
881
882 **Figure 5:** *KDM6B and IL-11 contribute to epithelial cell integrity in response to pneumococcus*. A549 cells
883 untreated or treated with 10 µM GSK-J4 or 100 ng/mL recombinant human IL-11 prior to 2hr challenge
884 with either TIGR4 (MOI 20) or 6B (MOI 20). Post-challenge cells were incubated with Trypan blue for cell
885 integrity, fixed with 2.5% paraformaldehyde and imaged with a brightfield microscope. A) Representative
886 image of GSK-J4 treated A549 cells post 2 hr challenge. Scale = 100µM. B) % Trypan positive cells between
887 untreated and GSK-J4 treated (pink) (n=4; 200-300 cells per replicate and group). Uninfected white, TIGR4
888 gray and 6B blue. Tukey box and whisker plot. C) Representative image of IL-11 treated A549 cells post 2
889 hr challenge. Scale = 100 µM. D) % Trypan positive cells between untreated and IL-11 treated (green) (n=4;
890 200-300 cells per replicate and group). Uninfected white, TIGR4 gray and 6B blue. Tukey box and whisker
891 plot. E) Total RNA harvested from A549 cells 2 hrs post-challenge with isolates of serotypes 6B, 19F, 19A,
892 and two isolates of 1 (hemolytic and non-hemolytic Ply; n=3 per isolate). Relative expression of *IL-11* to
893 uninfected cells. All data analyzed by One way-ANOVA with Tukey's multiple comparison post-hoc test,
894 **= pV≤0.01, ***= pV≤0.001, ns=not significant.
895
896 **Figure 6:** *KDM6B is required for host response to serotype 6B*. C57B6 mice (8-9 weeks) were challenged
897 intranasally with 3 - 4x10^6 CFU of TIGR4 or 6B supplemented with either DMSO (vehicle control), 5 mM

898 GSK-J4 or 0.15 ug recombinant mouse IL-11. At indicated endpoints bacterial load was enumerated by
899 conventional CFU counts on 5 µg/mL Gentamicin Columbia Blood agar selection plates from the nasal
900 lavage (NL), bronchoalveolar lavage fluid (BALF), lungs, and spleen of infected animals. A) 6B and TIGR4 ±
901 GSK-J4 with matched DMSO controls challenged animals 48 hrs post-inoculation CFU burden of indicated
902 samples (n=9). DMSO TIGR4 white, GSK-J4 TIGR4 gray, DMSO 6B light blue, GSK-J4 6B dark blue. B) TIGR4
903 ± IL-11 challenged animals 48 hrs post-inoculation CFU burden of indicated samples (n=9). TIGR4 (gray;
904 n=9) and TIGR4 + IL-11 (green; n=9). Tukey box and whisker plot with dots representing outliers. One way-
905 ANOVA non-parametric Kruskal-Wallis with Dunn's multiple comparison post-hoc test, *= pV≤0.05, **=
906 pV≤0.01, ***= pV≤0.001, ns=not significant. CFU=colony forming unit. Dotted lines =Limit of detection
907 (LD). LD for each organ: NL (50 CFU); BALF, Lung and Spleen (1000 CFU). X indicates animal died prior to
908 endpoint. C) Percent initial body weight TIGR4 gray and TIGR4 + IL-11 green. Solid lines represent Std.
909 Dashed line indicates 20% weight loss threshold. Repeated measures ANOVA with Tukey's multiple
910 comparison post-hoc test, **= pV≤0.01, ***= pV≤0.001.
911
912

Figure 1


180mm
Figure 1
80mm
A
% Survival
Days
TIGR4 (~3-4x10⁶)
6B (~3-4x10⁶)
6B (~3-4x10⁷)
***
***
B
% Body weight
Days
TIGR4
6B
6B
C
A549 Cells
6B
TIGR4
Avg. rel. expression to uninfected (log2)
-0.24 -0.19 - BCL2
3.39 2.10 - CCL2
1.57 -0.05 - CCL3
0.10 1.27 - CCL4
0.73 0.39 - CCL5
4.44 2.42 - CSF2
3.02 1.56 - CXCL1
0.49 0.61 - CXCL10
0.40 -1.17 - CXCL11
3.41 1.92 - CXCL2 (pV=0.026)
3.38 2.38 - CXCL3
0.25 -0.29 - CXCL5
-0.21 -1.00 - EGFR
5.73 6.23 - FOS
-0.05 0.49 - GADD45B
1.16 -0.27 - ICAM1
0.33 -0.24 - IL10
2.62 0.51 - IL11 (pV=0.001)
-0.05 -0.60 - IL15
-0.85 0.27 - IL17C
0.12 0.80 - IL17RE
4.23 3.54 - IL18
2.45 2.23 - IL1A
0.39 -0.42 - IL1B
-0.02 -0.16 - IL25
-0.14 0.12 - IL33
4.50 3.36 - IL6
5.09 4.43 - IL8
1.83 1.26 - JUNB
2.61 0.12 - KDM6B (pV=0.007)
1.31 0.63 - NLRP3
-0.49 -0.38 - PTAFR
2.37 2.05 - PTGS2
-0.17 -0.67 - RELA (pV=0.026)
1.19 0.02 - RELB
-0.17 -0.93 - TLR2
-0.57 -1.04 - TLR9
1.06 1.09 - TNF
-0.55 -0.75 - TNFRSF1A
0.10 -0.25 - TNFSF9
0.31 -0.71 - TRAF1
D
PC2 (18.8%)
PC1 (56.1%)
TIGR4
6B
IL-1β
E
Ratio KDM6B / DAPI
****
****
****
ns
Un
6B
PFA 6B
TIGR4
PFA TIGR4

987 **Figure 2**

988



989

990 **Figure 3**

991



992

Figure 4

180mm

Figure 4

80mm

A

	6B GSK - J4 − n=5	6B GSK - J4 + n=5
FOS	5.7305	6.4462
IL8	5.0880	2.9652
IL6	4.4963	2.3131
CSF2	4.4448	0.3422
IL18	4.2329	-0.3248
CXCL2	3.4115	1.7814
CCL2	3.3946	0.3872
CXCL3	3.3836	1.8896
CXCL1	3.0221	1.4691
IL11	2.6165	0.3954
KDM6B	2.6110	0.4471
IL1A	2.4536	1.2240
PTGS2	2.3725	1.8650
JUNB	1.8350	1.7408
CCL3	1.5706	-0.2809
NLRP3	1.3096	-0.6824
RELB	1.1917	0.0944
ICAM1	1.1599	0.8040
TNF	1.0606	0.7379
CCL5	0.7330	1.1383
CXCL10	0.4905	-2.7024
CXCL11	0.3976	2.1452
IL1B	0.3900	-0.3738
IL10	0.3336	1.7568
TRAF1	0.3053	0.5105
CXCL5	0.2462	0.3847
IL17RE	0.1236	0.3613
CCL4	0.1036	0.7957
TNFSF9	0.0962	-0.0005
IL25	-0.0228	0.3723
GADD45B	-0.0465	0.0891
IL15	-0.0538	-0.4745
IL33	-0.1424	-0.7470
RELA	-0.1707	-0.6153
TLR2	-0.1748	0.1244
EGFR	-0.2101	0.3309
BCL2	-0.2442	0.1640
PTAFR	-0.4887	0.2336
TNFRSF1A	-0.5532	-0.7146
TLR9	-0.5749	0.0461
IL17C	-0.8525	0.4319

B

	TIGR4 IL-11 − n=5	TIGR4 IL-11 + n=4
FOS	6.2287	4.8920
IL8	4.4259	2.7926
IL18	3.5369	-2.6739
IL6	3.3635	1.6475
CSF2	2.4190	0.2306
CXCL3	2.3796	1.1403
IL1A	2.2319	3.5441
CCL2	2.0990	-0.1975
PTGS2	2.0470	0.3610
CXCL2	1.9220	0.3976
CXCL1	1.5597	0.3264
CCL4	1.2650	-0.4132
JUNB	1.2611	0.7436
TNF	1.0946	-0.0925
IL17RE	0.7984	-0.7338
NLRP3	0.6311	-0.2850
CXCL10	0.6146	1.4877
IL11	0.5078	-0.3797
GADD45B	0.4934	0.8217
CCL5	0.3851	0.2217
IL17C	0.2738	-0.1238
KDM6B	0.1243	-1.6180
IL33	0.1189	-0.2018
RELB	0.0187	-2.0117
CCL3	-0.0497	-1.9036
IL25	-0.1648	-0.0335
BCL2	-0.1938	0.4221
IL10	-0.2355	-1.4032
TNFSF9	-0.2536	-0.1897
ICAM1	-0.2676	-2.6437
CXCL5	-0.2900	-0.9126
PTAFR	-0.3784	-0.6111
IL1B	-0.4207	0.2427
IL15	-0.5970	-0.1632
RELA	-0.6653	-2.4968
TRAF1	-0.7121	-1.7825
TNFRSF1A	-0.7469	-1.2192
TLR2	-0.9266	-0.3750
EGFR	-1.0041	-1.5796
TLR9	-1.0434	-1.4538
CXCL11	-1.1656	0.2890

6 4 2 0 -2

Avg. rel. expression to mactched uninfected (log_2)

C



D



Figure 5


180mm
Figure 5
80mm
A
Un
TIGR4
6B
DMSO
+ GSK-J4
B
% Trypan Positive Cells
NS
***
DMSO - Un
GSK - Un
DMSO - TIGR4
GSK - TIGR4
DMSO - 6B
GSK - 6B
C
Un
TIGR4
6B
-
+ IL-11
D
% Trypan Positive Cells
**
+ IL-11
(-) (+)
Un
TIGR4
6B
E
IL-11 Relative Expression to Uninfected
6B
19F
19A
1 (hemolytic Ply)
1 (non-hemolytic Ply)

998 **Figure 6**

999



1000